Examiner Initials BB) W6· 0 8 Cite No.	<u>ধ্</u>	Issue Date 03/26/85 12/10/85 02/04/86	U.S. PATENT DOC Applica	ant / Patentee		Group Art Unit	t: 1615
Examiner Initials BB	Cite No. 2 3 4 5 6 7	Serial Edatent Namber 3,507,466 4,558,120; 4,568,737; 4,587,329; 4,631,337;	03/26/85 12/10/85 02/04/86	U.S. PATENT DOC Applica	UMENTS ant / Patentee			
Examiner Initials BB	Cite No. 2 3 4 5 6 7	Serial Patent Namber 3,507,466 4,558,120; 4,568,737; 4,587,329; 4,631,337;	03/26/85 12/10/85 02/04/86	Applica	ant / Patentee	Class	Subclass	Filing Date
BB	2 3 4 5 6 7	Serial Flatent Member 4,507,466 4,558,120; 4,568,737; 4,587,329; 4,631,337;	03/26/85 12/10/85 02/04/86	Топ		Class	Subclass	Filina Date
BB	2 3 4 5 6 7	4,558,120; 4,568,737; 4,587,329; 4,631,337;	12/10/85 02/04/86		nalia <i>et al</i>	1		- ming Date
	2 3 4 5 6 7	4,558,120; 4,568,737; 4,587,329; 4,631,337;	02/04/86	Топ	03/26/85 Tomalia et al.		332	01/07/83
	4 5 6 7	4,587,329; 4,631,337;			nalia <i>et al</i> .	528	363	12/27/83
	5 6 7	4,631,337;	05/06/86	Ton	nalia <i>et al</i> .	528	332	08/14/84
	6		00,00,00	Топ	nalia <i>et al</i> .	528	363	07/19/85
	7	4,694,064;	12/23/86	Ton	nalia <i>et al</i> .	528	391	07/15/85
			09/15/87	Ton	nalia <i>et al.</i>	528	332	02/28/86
	8	4,713,975;	12/22/87	Тол	nalia <i>et al</i> .	73	865.8	05/30/86
		4,737,550;	04/12/88		omalia	525	418	12/08/86
	9	4,857,599;	08/15/89	Ton	nalia <i>et al</i> .	525	259	02/08/88
	10	4,871,779;	10/03/89	Ki	llat <i>et al</i> .	521	28	12/23/85
	11	5,338,532;	08/16/94	Ton	nalia <i>et al</i> .	424	1.49	. 02/13/91
	12	5,387,617;	02/07/95	Heds	trand et al.	521	79	11/08/93
	13	5,393,797;	02/28/95	Heds	trand et al.	521	134	06/13/94
	14	5,393,795;	02/28/95	Heds	strand et al.	521	134	06/13/94
	15	5,527,524;	06/18/96	Топ	nalia <i>et al</i> .	424	1.33	04/05/93
	16	5,560,929;	10/01/96	Heds	strand <i>et al</i> .	424	486	11/12/93
	17	5,773,527;	06/30/98	Топ	nalia <i>et al</i> .	. 525	417	01/20/95
	18	5,631,329;	05/20/97	Y	in et al.	525	417	03/21/95
	19	5,902,863;	05/11/99	Dvo	ornic <i>et al</i> .	525	431	07/21/97
	20	5,795,582;	08/18/98	,	Wright	424	400	02/07/96
	21	5,898,005;	04/27/99	Sii	ngh <i>et al</i> .	436	527	04/13/94
	22	5,861,319;	01/19/99	L	in et al.	436	527	10/28/94
	23	5,661,025;	08/26/97	Sz	oka et al.	435	172.3	06/07/95
	24	4,946,778;	08/07/90	Lac	dner et al.	435	69.6	01/19/89
	25	5,935,114;	08/10/99	Ja	ing et al.	604	264	12/09/96
	26	5,908,413;	06/01/99	La	nge <i>et al</i> .	604	529	10/03/97
	27	5,792,105;	08/11/98	l.	in <i>et al</i> .	604	96	09/11/96
	28	5,693,014;	12/02/97	At	xele et al.	604	96	05/15/95
	29	5,674,192;	10/07/97	Saha	atjian <i>et al</i> .	604	28	07/23/93
	30	5,876,445;	03/02/99	And	ersen <i>et al</i> .	623	11	11/26/96
	31	5,913,894;	06/22/99		Schmitt	623	1 .	10/20/95
	32	5,868,719;	02/09/99	T	sukernik	604	265	01/15/97
V	,, I	5,851,228;	12/22/98	F	Pinheiro	623	1	08/22/96
Examiner:	33	Examiner: /Bethany Barham/ Date Considered: 10/19/2006						

FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.: UM-06609 Applicant: James R. Baker, Jr. et al. Serial No.: 09/940,243

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)

Examiner Initials No. BB 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	Serial / Patent Number 5,843,089; 5,800,519; 5,800,508; 5,800,391; 5,354,308; 5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,892,020; 5,892,019; 5,512,443; 5,693,763 5,545,530;	Issue Date 12/01/98 09/01/98 09/01/98 09/01/98 10/11/94 05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97 08/13/96	Applicant / Patentee Sahatjian et al. Sandock Goicoechea et al. Kontos Simon et al. Barry et al. Ungs Barry Meek Mezes et al. Schlom et al. Schlom et al. Codington et al. Satomura et al.	Class 606 623 623 604 606 606 606 514 604 345 536 435 530 435	Subclass 108 1 96 198 108 198 108 23.53 23.53 7.23 387.7 6	Filing Date 09/20/96 11/04/96 06/05/95 03/15/96 05/01/92 12/22/94 05/31/95 08/21/97 06/02/97 06/07/95 09/01/94 07/02/90 06/06/95
BB 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,843,089; 5,800,519; 5,800,508; 5,800,391; 5,354,308; 5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	12/01/98 09/01/98 09/01/98 09/01/98 10/11/94 05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Sahatjian et al. Sandock Goicoechea et al. Kontos Simon et al. Barry et al. Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	606 623 623 604 606 606 514 604 345 536 435	108 1 1 96 198 108 198 108 198 348 23.53 23.53 7.23 387.7	09/20/96 11/04/96 06/05/95 03/15/96 05/01/92 12/22/94 05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90 06/06/95
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,800,519; 5,800,508; 5,800,391; 5,354,308; 5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	09/01/98 09/01/98 09/01/98 10/11/94 05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Sandock Goicoechea et al. Kontos Simon et al. Barry et al. Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Codington et al.	623 623 604 606 606 606 514 604 345 536 435	1 1 96 198 108 198 182 96 348 23.53 23.53 7.23 387.7	11/04/96 06/05/95 03/15/96 05/01/92 12/22/94 05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90 06/06/95
36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,800,508; 5,800,391; 5,354,308; 5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	09/01/98 09/01/98 10/11/94 05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Goicoechea et al. Kontos Simon et al. Barry et al. Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	623 604 606 606 606 514 604 345 536 435	96 198 108 198 182 96 348 23.53 23.53 7.23	06/05/95 03/15/96 05/01/92 12/22/94 05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,800,391; 5,354,308; 5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	09/01/98 10/11/94 05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Simon et al. Barry et al. Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Codington et al.	604 606 606 606 514 604 345 536 435	96 198 108 198 182 96 348 23.53 23.53 7.23	03/15/96 05/01/92 12/22/94 05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,354,308; 5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	10/11/94 05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Simon et al. Barry et al. Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Codington et al.	606 606 606 514 604 345 536 536 435	198 108 198 182 96 348 23.53 23.53 7.23	05/01/92 12/22/94 05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90
39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,755,722; 5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	05/26/98 03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Barry et al. Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	606 606 514 604 345 536 536 435	108 198 182 96 348 23.53 23.53 7.23	12/22/94 05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	5,733,303 5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	03/31/98 02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96	Israel et al. Ungs Barry Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	606 514 604 345 536 536 435 530	198 182 96 348 23.53 23.53 7.23 387.7	05/31/95 08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90 06/06/95
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,866,561; 5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	02/02/99 01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Ungs Barry Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	514 604 345 536 536 435	182 96 348 23.53 23.53 7.23 387.7	08/21/97 06/02/97 04/17/97 06/07/95 09/01/94 07/02/90 06/06/95
42 43 44 45 46 47 48 49 50 51 52 53 54 55	5,857,998; 5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	01/12/99 withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	345 536 536 435	96 348 23.53 23.53 7.23 387.7	06/02/97 04/17/97 06/07/95 09/01/94 07/02/90 06/06/95
43 44 45 46 47 48 49 50 51 52 53 54 55	5,843,003; 5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	withdrawn 08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Meek Mezes et al. Schlom et al. Schlom et al. Codington et al.	345 536 536 435 530	348 23.53 23.53 7.23 387.7	04/17/97 06/07/95 09/01/94 07/02/90 06/06/95
44 45 46 47 48 49 50 51 52 53 54 55	5,933,145; 5,892,020; 5,892,019; 5,512,443; 5,693,763	08/03/99 04/06/99 04/06/99 04/30/96 12/02/97	Mezes et al. Schlom et al. Schlom et al. Codington et al.	536 536 435 530	23.53 23.53 7.23 387.7	06/07/95 09/01/94 07/02/90 06/06/95
45 46 47 48 49 50 51 52 53 54 55	5,892,020; 5,892,019; 5,512,443; 5,693,763	04/06/99 04/06/99 04/30/96 12/02/97	Mezes et al. Schlom et al. Schlom et al. Codington et al.	536 536 435 530	23.53 23.53 7.23 387.7	06/07/95 09/01/94 07/02/90 06/06/95
46 47 48 49 50 51 52 53 54 55	5,892,019; 5,512,443; 5,693,763	04/06/99 04/30/96 12/02/97	Schlom et al. Schlom et al. Codington et al.	536 435 530	23.53 7.23 387.7	09/01/94 07/02/90 06/06/95
47 48 49 50 51 52 53 54 55	5,512,443; 5,693,763	04/30/96 12/02/97	Schlom et al. Codington et al.	435 530	7.23 387.7	07/02/90 06/06/95
48 49 50 51 52 53 54 55	5,693,763	12/02/97	Codington et al.	530	387.7	06/06/95
50 51 52 53 54 55 56						
50 51 52 53 54 55 56	5,545,530;	08/13/96	Satomura et al.	435	6	05/17/95
51 52 53 54 55 56		, , , , , , , , , , , , , , , , , , ,				
52 53 54 55 56	5,808,005;	09/15/98	Codington et al.	530	395	06/06/95
53 54 55 56	4,708,930;	11/24/87	Kortright et al.	435	7	02/15/85
54 55 56	4,743,543;	05/10/88	Kortright	435	7	09/09/85
55 56	4,921,789;	05/01/90	Salem et al.	435	7	04/20/88
56	4,921,790;	05/01/90	O'Brien	435	7	04/24/87
	5,110,911;	05/05/92	Samuel et al.	530	395	11/02/89
57	5,855,866	01/05/99	Thorpe et al.	424	1.49	03/02/94
	4,963,484;	10/16/90	Kufe	435	69.3	01/29/88
58	5,053,489;	10/01/91	Kufe	530	350	01/27/89
59	4,939,240	07/03/90	Chu et al.	530	387	09/11/85
60	4,918,164;	04/17/90	Hellstrom et al.	530	387	11/04/87
61		04/03/90	Toth et al.	435	7	03/04/88
62		01/09/90	Yoshida <i>et al</i> .	530	387	07/06/87
63		12/12/95	Gold et al.	563	23.1	06/10/91
64		12/14/93	Gold et al.	435	6	08/17/92
65		02/03/98	Tomalia et al.	424	486	03/07/95
aminer:	ı	nam/	·····		/19/2006	

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of (Modified) Patent and Tradema			ment of Commerce	Attorney Docket No.: UM-06609 Set		Serial No.: 09	Serial No.: 09/940,243			
"""	•	RMATIC	N DISCLOSURE ST	TATEMENT BY AP		Applicant: James R. Baker, Jr. et al.				
(Use Several Sheets If Necessary) (37 CFR § 1.98(b)) Filing Date: 08/27/20					Filing Date: 08/27/2001	01 Group Art Unit: 16/5			5	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS										
	TOREIGN TATE OF TOREIGN TATE OF THE OFFICE OFFICE OFFICE OFFICE OFFICE OFFICE OFFICE O				Translation					
	Document Number Publication Date Country / Patent Office Class				Subclass	Yes	No			
BI	В	66	WO 97/38134 PCT							
		67	WO 98/33941;			РСТ				
		68	WO 99/07724;		PCT					
		69	PCT/US90/02545		PCT					
		70	WO 99/02651			PCT				
>										
	,		OTHER	DOCUMENTS (Incl	uding Author, Title, D	ate, Relevant Pages, Place o	f Publication)			
BI	3	71	Friedman, Cancer 70	0:1810 [1992]						
		72	Kerr et al., Cancer 7	3:2013 [1994];						
		73	Cohen and Tohoku, Exp. Med., 168:351 [1992];							
		74	Fujiwara et al., J. Natl. Cancer Inst., 86:458 [1994];							
		75	Tomalia, Advanced Materials 6:529 [1994];							
		76	Tomalia, Angew, Chem. Int. Ed. Engl., 29:138 [1990]							
		77	Tomalia et al., Chen	Tomalia et al., Chem. Int. Ed. Engl., 29:5305 [1990];						
		78	Yin et al., J. Am. Cl	nem. Soc., 120:2678 [1998];					
		79	Roberts et al., J. Biomed. Mat. Res., 30:53 [1996]							
		.80	Bourne et al., J. Magn. Reson. Imag., 6:305 [1996];							
		81	Singh et al., Clin. Chem., 40:1845 [1994];							
		82	Wu et al., Bioorg. Med. Chem. Lett., 4:449 [1994];							
		83	Wiener et al., Magn. Reson. Med, 31:1 [1994]							
		84 Barth et al., Bioconjugate Chem. 5:58 [1994];								
		88 Duncan and Malik, Control Rel. Bioact. Mater. 23:105 [1996];								
		86	Baker et al., Anal. Chem. 69:990 [1997];							
		87	Urdea and Hom, Science 261:534 [1993];							
		88	Lanni et al., Proc. Natl. Acad. Sci., 94:9679 [1997];							
		89	Tortora et al., Cancer Research 57:5107 [1997];							
		90	Zaffaroni et al., Brit. J. Cancer 77:1378 [1998]:							
		91	Yu et al., Molecular	Cell. 2:581 [1998];				ä		
		92	Gibb, Gynecologic (Oncology 65:13 [1997	'];					
		93	Akutsu et al., Eur. J	. Cancer 31A:2341 [1	995];					
$lgsup \Psi$		94	Goodman and Gilms being supplied at the	an's "Pharmaceutical l s time.	Basis of Therapeutics*	ninth edition, Eds. Hardma	un <i>et al</i> ., 1996. T	This reference is a	book and	is not
Examin	er:		/Bethany Ba			Date Considered:	10/19/	2006		
EXAM	EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Attorney Docket No.: UM-06609 Serial No.: 09/940,243 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Applicant: James R. Baker, Jr. et al. Group Art Unit: 1015 (37 CFR § 1.98(b)) Filing Date: 08/27/2001 OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) BB 95 Pasani et al., Inorg. Chim. Acta 80:99 [1983] 96 Ottl et al., Bioconjugate Chem., 9:143 [1998]; Abel et al., Eur. J. Cancer 9:4 [1973]; 97 .98 Pillai, V.N.R. Synthesis: 1-26 [1980]; 99 Esfand et al., Pharm. Sci., 2:157 [1996]; 100 Vasey et al., Clin. Cancer Res., 5:83 [1999]; 101 Capala et al., Bioconjugate Chem., 7:7 [1996] Selman, et al., Photochem. Photobiol., 57:681-85 [1993]; 102 103 Brasseur et al., Photochem. Photobiol., 47:705-11 [1988]; 104 Firey and Rodgers, Photochem. Photobiol., 45:535-38 [1987]; 105 Sessler et al., Proc. SPIE, 1426:318-29 [1991]; 106 Chang et al., Proc. SPIE, 1203:281-86 [1990]; 107 Cincotta et al., SPIE Proc., 1203:202-10 [1990]; 108 Pandey et al., Photochem. Photobiol., 53:65-72 [1991]; 109 Botchway et al., Photochem. Photobiol. 67(7):635-40 [1998]; 110 Liao et al., PNAS 91:2659 [1994]; 111 Haugland, Handbook of Fluorescent Probes and Research Chemicals, 6th ed. This reference is a book and is not being supplied at this time. 112 Murphy et al., Neuropharm. 33:1375-85 [1994]; 113 Bourassa et al., JACS 119:2853-60 [1997]; 114 De Leo and Ford, JACS 121:1980-81 [1999]; 115 Chan and Nie, Science 281:2016 [1998]; 116 Sooklal, Adv. Mater., 10:1083 [1998] 117 Balogh et al., Proc. of ACS PMSE 77:118 [1997]; 118 Balogh and Tomalia, J. Am. Che. Soc., 120:7355 [1998]; 119 Wiener et al., Mag. Reson. Med. 31:1 [1994]; 120 Wong et al., Ivest. Rad. 31:26 [1996]; 121 Farkas et al., SPEI 2678:200 [1997]; 122 Lester et al., Cell Mol. Biol. 44:29 [1998]; 123 Shortreed et al., J. Phys. Chem., 101:6318 [1997]; 124 Talanian et al., J. Biol. Chem., 272: 9677 [1997]; 125 Abrams et al., Development 117:29 [1993]; 126 Hockenbery et al., Cell 75:241 [1993]; 127 Wiener et al., Invest. Radiol., 32:748 [1997]; 128 Capale et al., Bioconjugate Chem., 7:7 [1996]; 129 Penault-Llorca et al., Int. J. Cancer 61:170 [1995]; 10/19/2006 /Bethany Barham/ Date Considered: Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **EXAMINER:**

FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Attorney Docket No.: UM-06609 Serial No.: 09/940,243 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Applicant: James R. Baker, Jr. et al. Group Art Unit: (37 CFR § 1.98(b)) Filing Date: 08/27/2001 OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) BB 130 Press et al., Oncogene 5:953 [1990]; 131 Pegram et al., Proc. Am. Soc. Clin. Oncol., 14:106 [1995]; 132 Park et al., Cancer Lett., 118:153 [1997]; 133 Kirpotin et al., Biochem., 36:66 [1997] 134 Kjeldsen et al., Cancer Res. 48:2214-2220 [1988]; 135 Springer et al., Carbohydr. Res. 178:271-292 [1988]; 136 Tjandra et al., Br. J. Surg. 75:811-817 [1988]; 137 Ishida et al., Tumor Biol. 10:12-22 [1989]; 138 Lan et al., Cancer Res. 45:305-310 [1985]; 139 Hanisch et al., Carbohydr. Res. 178:29-47 [1988]; 140 Hinoda et al., (1988) Cancer J. 42:653-658 [1988]: Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. This reference is a book and is not being supplied at this time. 141 142 Köhler and Milstein, Nature 256:495-497 [1975]; 143 Kozbor et al. Immunol. Today 4:72 [1983]; 144 Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985] 145 Cote et al., Proc. Natl. Acad. Sci. U.S.A.80:2026-2030 [1983]; 146 Huse et al., Science 246:1275-1281 [1989]; 147 Duncan et al., Polymer Preprints 39:180 [1998]; 148 Sharon and Lis, Science 246:227 [1989]; 149 Monsigny et al., Biochemie 70:1633 [1988]; 150 Page and Roy, Bioconjugate Chem., 8:714 [1997]; 151 Cortese et al., Curr. Opin. Biotechol., 6:73 [1995]; 152 Goodwin and Meares, Cancer (suppl.) 80:2675 [1997]; 153 Wilbur et al., Bioconjugate Chem., 9:813 [1998]; 154 Barth et al., Cancer Investigation 14:534 [1996]; 155 Duncan and Sat, Ann. Oncol., 9:39 [1998]; Malik et al., Proc. Int'l. Symp. Control. Rel. Bioact. Mater., 24:107 [1997] 156 157 Wies et al., Nature 333: 426 [1988]; 158 White et al., Cell 56: 725 [1989]; 159 Wyrick et al., Infect. Imm. 57: 2378 [1989]; 160 Adlish et al., Virology 176: 337 [1990]; 161 Krah, Virology 172: 386 [1989] 162 Khatzman et al., Nature 312: 763 [1985]; 163 Sacerdote et al., J. of Neuroscience Research 18: 102 [1987]; 10/19/2006 /Bethany Barham/ Examiner: Date Considered: **EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Attorney Docket No.: UM-06609 Serial No.: 09/940,243 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Applicant: James R. Baker, Jr. et al. Group Art Unit: (6) Filing Date: 08/27/2001 (37 CFR § 1.98(b)) OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) 33 164 Ruff et al., FEBS Letters 211: 17 [1987]; 165 Epstein et al., Nature 318: 663 [1985]; 166 Lentz et al., Science 215: 182 [1982]; 167 Carel et al., J. Biol. Chem. 265: 12293 [1990]; 168 Co et al., Proc. Natl. Acad. Sci. 82: 1494 [1985]; 169 Marlin et al., Nature 344: 70 [1990]; 170 Shephey et al., Proc. Natl. Acad. Sci. 85: 7743 [1988] 171 Mendelsohn et al., Cell 56: 855 [1989] 172 Kaner et al., Science 248: 1410 [1990]; 173 Tuerk et al., Gene 137(1):33-9 [1993]; 174 Binkley et al., Nuc. Acids Res. 23(16):3198-205 [1995]; 175 Jellinek et al., Biochem. 83(34):10450-6 [1994]; 176 Uppuluri et al., PMSE 80:55 [1999]; 177 Mosmann, J. Immunol. Meth., 65:55 [1983] 178 Kuhlmann et al., Arch. Toxicol., 72:536 [1998]; 179 Bielinska et al., Nucleic Acids Research 24:2176-2182 (1996) 180 Kukowska-Latallo et al., Proc.Natl. Acad. Sci. USA 93:4897-4902 (1996) 181 Bielinska et al., Biochimica et Biophysica Acta 1353:180-190 (1997) 182 Wagner, Journal of Controlled Release 53:155-158 (1998) 183 Brazeau et al., Pharm. Research 15:680-684 (1998) 184 Shchepinov et al., Nucleic Acids Research 25:4447-4454 (1997) 185 Haensler et al., Bioconjugate Chem. 4:373-379 (1993) 186 Orentas et al., Journal of Virological Methods 77:153-163 (1999) 187 Choi et al., Bioconjugate Chem. 10:62-65 (19999) 188 Ruponen et al., Biochimica et Biophysica Acta 1415:331-341 (1999)

Examiner:

/Bethany Barham/

Pratap Singh, Bioconnugate Chem., 9:54-63 [1998]

Zhou et al., Journal of Controlled Release 57:249-257 [1999]

Date Considered:

10/19/2006

EXAMINER:

189

190

191

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Baker et al., Kluwer Academic Publishers, Manufactured in the Netherlands 61-690 (2001)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known			
	Application Number	10/402,287 09940243		
INFORMATION DISCLOSURE	Filing Date	08/27/01		
	First Named Inventor	Baker		
STATEMENT BY APPLICANT	Art Unit	1635~ 1レ1の		
(Use as many sheets as necessary)	Examiner Name	Ashen BARHAM		
Sheet 7 of 7	Attorney Docket Number	UM-06609		

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (F known)}			Figures Appear	
		US-				
		US-				
		Ü\$-				
		US-				
		US-	1			
- .	<u> </u>	US-	1			
		US-	 			
		US-	- 			
		US-				
		US-				
		US-	 			
		US-				
		US-				
	<u> </u>	US-	 			
		US-	1		1	
		US-	- 			
		US-	1		 	
		US-				
		US-	 		 	

xaminer	Cite	Foreign Patent Document	IGN PATENT DOCL	Name of Patentee or	Pages, Columns, Lines,	Т
ritials*	No.1		Date	Applicant of Cited Document	Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁹ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
BB 19		WO 99/61662	02/12/99	PCT		
	193	WO 97/07398	27/02/97	PCT		
		WO 01/02861	11/01/01	PCT		L
	195	EP 0 271 180	15/06/1988	EP		
1/						I
₩	<u> </u>					

	•		
Examiner Signature	/Bethany Barham/	Date Considered	10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.